Page last updated: 2024-08-24

irinotecan and Cancer of Esophagus

irinotecan has been researched along with Cancer of Esophagus in 131 studies

Research

Studies (131)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (1.53)	18.2507
2000's	67 (51.15)	29.6817
2010's	46 (35.11)	24.3611
2020's	16 (12.21)	2.80

Authors

Authors	Studies
Adenis, A; Al-Rajabi, R; Amonkar, M; Bhagia, P; de la Fouchardiere, C; Girotto, GC; Kulkarni, AS; Mansoor, W; Metges, JP; Norquist, J; Senellart, H; Suryawanshi, S; van Laarhoven, HWM	1
Bai, C; Bai, Y; Chen, X; Cui, C; Cui, T; Dai, G; Fan, Q; Gao, Q; Gu, K; Huang, Y; Ji, S; Li, W; Li, Y; Liao, W; Liu, Y; Ma, D; Ma, Z; Mancao, C; Peng, B; Shu, Y; Sun, J; Tao, M; Wang, J; Wang, X; Wang, Y; Wu, L; Xiao, J; Xu, J; Xu, N; Yang, L; Yang, Y; Zhang, J; Zhang, T; Zhang, Y; Zhou, H	1
Chang, J; Hu, Z; Sun, S; Wang, H; Wang, J; Wu, X; Yu, H; Zhao, X	1
Cai, G; Cai, X; Chen, Y; Gong, Y; Ke, S; Qiu, H; Ruan, S; Shi, W; Wu, Y; Zhao, W; Zuo, Z	1
Bian, W; Chen, S; Dai, X; Tao, L; Wang, J; Wu, W	1
Adenis, A; Barbier, E; Borg, C; Breysacher, G; Dahan, L; Desrame, J; Di Fiore, F; Faroux, R; Gaba, L; Laurent-Puig, P; Lièvre, A; Lopez, A; Louafi, S; Louvet, C; Manfredi, S; Metges, JP; Mineur, L; Randrian, V; Roquin, G; Tougeron, D	1
Chen, Y; Gubat, JA; Jia, Q; Li, Y; Liu, M; Min, L; Sun, C; Wang, X; Yang, J; Zhang, X; Zhu, C	1
Gong, LB; Wu, W; Yu, GM; Zhang, C; Zhang, M	1
Allen, K; Alpert, L; Catenacci, DVT; Chase, L; de Wilton Marsh, R; Ferguson, MK; Gordon, B; Hart, J; Karrison, T; Kindler, HL; Kipping-Johnson, K; Liao, CY; Lomnicki, S; Markevicius, U; Maron, SB; Moore, K; Narula, S; Peterson, B; Polite, BN; Posner, MC; Prachand, VN; Racette, C; Rampurwala, MM; Roggin, KK; Setia, N; Siddiqui, UD; Turaga, K; Xiao, SY	1
Ajani, JA; Blum Murphy, M; Palmer, M; Rogers, JE; Trail, A; Xiao, L	1
Bang, YJ; Chung, HC; Iwasa, S; Kamio, T; Kawaguchi, Y; Kawakami, H; Kojima, A; Lee, J; Ryu, MH; Saito, K; Sakai, D; Shitara, K; Sugihara, M; Sugimoto, N; Yabusaki, H; Yamaguchi, K	1
Acharya, A; Amin, M; Copsey, ML; Gao, F; Jin, RU; Lim, KH; Lockhart, AC; Morton, AE; Navo, KA; Park, H; Pedersen, KS; Rigden, C; Suresh, R; Tan, BR; Trikalinos, NA; Wang-Gillam, A	1
Adenis, A; Al-Rajabi, R; Bennouna, J; Bhagia, P; Chen, J; de la Fouchardiere, C; Doi, T; Enzinger, P; Ferreira, P; Francois, E; Girotto, G; Hsu, CH; Kang, SP; Kato, K; Kim, SB; Kojima, T; Lee, SH; Lordick, F; Metges, JP; Moriwaki, T; Muro, K; Qin, SK; Senellart, H; Shah, MA; Shen, L; Suryawanshi, S; Wang, R	1
Dou, Y; Fan, Q; Huang, J; Kou, X; Li, N; Li, Q; Liang, X; Liu, Y; Song, Y; Wang, X; Yin, X; Zhang, J; Zhang, S; Zhong, H; Zhuang, Z	1
Chai, K; Chen, J; Chen, L; Chen, M; Dong, C; Hu, X; Li, R; Lu, Y; Shi, S; Sun, Y; Wang, C; Yao, T; Zhou, L	1
Chang Lee, R; Hsieh, AH; Moldovan, M; Price, T; Tomita, Y; Townsend, A	1
Bueno, R; Catalano, PJ; Enzinger, PC; Hong, TS; King, BL; Mamon, HJ; Martin, NE; Sanford, NN; Wo, JY	1
Alessi, A; Battiston, C; Berenato, R; Caporale, M; Coppa, J; Cotsoglou, C; de Braud, F; Delconte, G; Di Bartolomeo, M; Fucà, G; Greco, G; Infante, G; Lazzati, S; Mazzaferro, V; Mennitto, A; Morano, F; Niger, M; Padovano, B; Pellegrinelli, A; Pietrantonio, F	1
Kitamura, S; Kuga, Y; Miwata, T; Mouri, T; Nishida, T; Sakimoto, H	1
Al-Batran, SE; Alsina, M; Bang, YJ; Boku, N; Chung, HC; Conti, I; Evesque, L; Hallwachs, R; Hong, J; Lee, KW; Lichinitser, M; Moehler, MH; Park, SH; Ruiz, EY; Ryu, MH; Schenker, M; Taieb, J; Van Cutsem, E; Wyrwicz, L; Xiong, H	1
Chen, L; Fu, MY; Tian, D; Wang, Y; Wen, HY; Zhang, KP; Zhang, L; Zhou, Y	1
Aieta, M; Chiriacò, G; Conca, R; Multari, AG; Paganini, G; Petrioli, R; Rosellini, P; Roviello, G	1
Ba, Y; Bai, Y; Cheng, Y; Fan, Q; Feng, J; Hu, C; Huang, J; Li, J; Liu, Y; Lu, P; Ma, C; Wang, X; Wen, L; Wu, L; Xu, B; Yuan, X; Zhang, S	1
Chen, J; Hua, Z; Lu, B; Lu, C; Qu, C; Sun, Z; Tong, R; Zhang, J	1
de Castria, TB; Fujiki, FK; Hoff, PMG; Takeda, FR; Victor, CR	1
Cardic, MB; Chao, Y; Chen, LT; Cunningham, D; de Gramont, A; Kang, YK; Kujundzic, M; Lim, HY; Park, SR; Ramos, FJ; Rees, C; Roy, AC; Tabernero, J; Yeh, CG	1
Bueno, R; Choi, NC; Donahue, DM; Enzinger, PC; Fidias, PM; Fuchs, CS; Hong, TS; Jaklitsch, MT; Kwak, EL; Lanuti, M; Lee, MS; Mamon, HJ; Meyerhardt, JA; Rattner, DW; Ryan, DP	1
Abe, T; Fukaya, M; Itatsu, K; Nagino, M; Yokoyama, Y	1
Gao, J; Li, Y; Peng, Z; Shen, L; Wang, X; Zhou, J	1
Bains, MS; Gerber, N; Goodman, KA; Ilson, DH; Janjigian, YY; Kelsen, DP; Rizk, N; Rusch, VW; Wu, AJ; Zhang, Z; Zheng, J	1
Asaoka, T; Fujitani, K; Hirao, M; Ikeda, M; Ikenaga, M; Miyamoto, A; Nakamori, S; Sekimoto, M; Takeoka, T; Yamamoto, K	1
Dasanu, CA; Nandy, N	1
Besanceney-Webler, C; Chen, EX; Cheng, J; Christos, P; Dilts, KT; Holloway, S; Keresztes, R; Lane, ME; Lin, J; Matulich, D; Ocean, AJ; Papetti, M; Schnoll-Sussman, F; Shah, MA; Sparano, JA; Ward, M; Wright, JJ; Xiang, J; Yantiss, RK	1
Hamaguchi, T; Honma, Y; Iwasa, S; Kato, K; Okita, N; Okuma, HS; Shimada, Y; Shoji, H; Takashima, A; Yamada, Y	1
Calkins, SM; Cinar, P; Kelley, RK; Venook, AP	1
Asaishi, K; Goto, M; Higuchi, K; Kii, T; Kurisu, Y; Kuwakado, S; Miyamoto, T; Nishitani, H; Shimamoto, F; Terazawa, T	1
Anne, PR; Benson, AB; Catalano, PJ; Forastiere, AA; Keller, SM; Kleinberg, LR; Mitchel, EP	1
Benson, AB; Burtness, BA; Cohen, SJ; Douglas, K; Enzinger, PC; Goldberg, RM; Ilson, DH; Mayer, RJ; Niedzwiecki, D; Venook, A; Villaflor, VM; Ye, X	1
Bueno, R; Choi, N; Cleary, JM; Donahue, DM; Enzinger, PC; Fidias, PM; Fuchs, CS; Gaissert, HA; Jaklitsch, MT; Kulke, MH; Lynch, TP; Mamon, HJ; Mentzer, SJ; Meyerhardt, JA; Swanson, RS; Szymonifka, J; Wain, J	1
Anderegg, MC; Haj Mohammad, N; Mali, RMA; Ngai, LL; Ter Veer, E; van Laarhoven, HWM; van Oijen, MGH; van Valkenhoef, G	1
Cheng, SY; Du, J; Li, J; Li, KC	1
Baba, S; Chin, K; Hatake, K; Hosaka, H; Ishiyama, A; Kozuka, T; Mizunuma, N; Seto, Y; Shinozaki, E; Suenaga, M; Yamamoto, N	1
Barone, C; Bugat, R; Cisar, L; Dank, M; Goker, E; Peschel, C; Valvere, V; Wang, K; Wenczl, M; Yalcin, S; Zaluski, J	1
Fujitani, K; Hirao, M; Ikenaga, M; Kashiwazaki, M; Masuzawa, T; Mishima, H; Nakamori, S; Takeda, M; Tsujinaka, T	1
Fujimitsu, Y; Kojima, H; Kojima, T; Kure, N; Matsui, T; Mochizuki, Y; Uemura, T	1
Assersohn, L; Brown, G; Chong, G; Costello, C; Cunningham, D; Higgins, L; Leary, A; Norman, AR; Oates, J; Ross, PJ	1
Blaszkowsky, LS; Clark, JW; Earle, CC; Enzinger, PC; Fidias, P; Fuchs, CS; Kulke, MH; Mayer, RJ; Meyerhardt, JA; Muzikansky, A; Ryan, DP; Vincitore, MM; Zhu, AX	1
Gennatas, C; Gennatas, S; Michalaki, V	1
Ilson, DH; Kelsen, DP; Ku, GY; Maki, RG; O'Reilly, EM; Saltz, LB; Schrag, D	1
Burtness, B; Egleston, B; Forastiere, AA; Gibson, M; Lacy, J; Mehra, R; Murren, JR; Quintanilla, M; Sipples, R; Thomas, L; Watkins, S	1
Hihara, J; Mizuiri, H; Okada, M	1
Bando, Y; Kenzaki, K; Kondo, K; Miyoshi, T; Ohnishi, Y; Sawada, N; Seike, J; Takizawa, H; Tangoku, A; Yamai, H; Yoshida, T	1
Alonso-Orduña, V; Antón, A; Aranda, E; Cardenal, A; Carrato, A; Cervantes, A; Escudero, P; Galán, M; Gallego, J; Giralt, J; Laquente, B; Massutí, B; Rivera, F; Rodríguez, E; Sáenz, A; Tabernero, J; Vega-Villegas, ME; Yuste, AL	2
Hirota, M; Ichihara, T; Nakamura, E; Yamashita, K	1
Aguero, EG; Garrett-Mayer, E; Reed, CE; Ruppert, BN; Sharma, AK; Sherman, CA; Shirai, K; Wahlquist, AE; Watkins, JM	1
Allegrini, G; Andreuccetti, M; Cascinu, S; Cortesi, E; Falcone, A; Fontana, E; Fornaro, L; Granetto, C; Loupakis, F; Masi, G; Mentuccia, L; Merlano, M; Salvatore, L; Vasile, E	1
Abbas, A; Bekaii-Saab, T; Burak, W; Lustberg, MB; Lustberg, ME; McCracken-Bussa, B; Otterson, G; Villalona-Calero, MA; Young, D	1
Heinemann, MH; Ilson, DH; Morris, PG; Oda, J	1
Chen, E; Darling, G; Guindi, M; Haider, M; Horgan, AM; Hornby, J; Keshavjee, S; Knox, JJ; Ringash, J; Visbal, AL; Wong, R; Xu, W	1
Aguero, EG; Harper, JL; Kearney, PL; Reed, CE; Ruppert, BN; Sharma, AK; Sherman, CA; Shirai, K; Watkins, JM; Zauls, AJ	1
Galle, PR; Geißler, M; Kanzler, S; Kubicka, S; Lordick, F; Moehler, M; Mueller, A; Schwarz, S; Seufferlein, T; Trarbach, T	1
Doi, K; Hirano, Y; Kudoh, K; Ogata, K; Ohchi, T	1
Ashley, S; Charalambous, H; Chau, I; Cunningham, D; Hawkes, E; Koukouma, A; Okines, AF; Papamichael, D; Rao, S	1
Bjerregaard, JK; De Stricker, K; Gjerstorff, MF; Hansen, TP; Jensen, HA; Pfeiffer, P; Schoennemann, KR; Vestermark, LW	1
Albrecht, H; Boxberger, F; Busse, D; Golcher, H; Hahn, EG; Hohenberger, W; Janka, R; Konturek, PC; Koucky, K; Männlein, G; Neurath, MF; Ostermeier, N; Reulbach, U; Schildberg, C; Siebler, J; Wein, A; Wolff, K	1
Ando, T; Fujinami, H; Hasumoto, Y; Hosokawa, A; Itaya, Y; Kajiura, S; Miyazaki, T; Nishikawa, J; Ogawa, K; Sugiyama, T; Suzuki, N; Ueda, A; Yamawaki, H	1
Abbas, F; Adenis, A; Afchain, P; Aparicio, T; Bécouarn, Y; Bouché, O; Desseigne, F; Dorval, E; Edeline, J; Guimbaud, R; Kramar, A; Mitry, E; Romano, O; Samalin, E; Thézenas, S; Ychou, M	1
Bains, M; Campbell, J; Capanu, M; Ilson, DH; Kelsen, DP; Ku, GY; Minsky, BD; Rizk, N; Rusch, V; Shah, M; Tang, L	1
Bjerregaard, JK; Nielsen, KM; Pfeiffer, P; Schønnemann, KR; Yilmaz, M	1
Fujiwara, N; Hoshino, A; Jirawat, S; Kawada, K; Kawano, T; Miyawaki, Y; Nagai, K; Nakajima, Y; Nishikage, T; Ohta, S; Okada, T; Ryotokuji, T; Tokairin, Y	1
Abbruzzese, JL; Beeker, T; Benedetti, JK; Blanke, CD; Gold, PJ; Goldman, BH; Lenz, HJ; Mehta, V; Thomas, CR; Tomblyn, MB	1
Adenis, A; Adler, G; Aparicio, J; Barcelo, JR; Canon, JL; Cassinello, J; Castanon, C; Cunningham, D; D'Hondt, L; Fonseca, E; Garcia Giron, C; Hawkins, R; Hossfeld, DK; Kerger, J; Lofts, F; Lopez-Vivanco, G; Misset, JL; Mousseau, M; Nicolson, M; Rixe, O; Rodriguez, R; Roy, A; Schalhorn, A; Schoffski, P; Sörbye, H	1
Ilson, DH; Ku, GY	1
Campbell, JC; Capanu, M; Ilson, DH; Janjigian, YY; Kelsen, DP; Ku, GY; Shah, MA	1
Ilson, DH; Kelsen, D; Minsky, B	1
Ajani, JA; Baker, J; Charnsangavej, C; Feig, BW; Ho, L; Mansfield, PF; Pisters, PW	2
Gallagher, CJ; Shamash, J; Slater, S; Slevin, ML; Wilson, P	1
Hinkelbein, W; Mühr-Wilkenshoff, F; Ohnesorge, I; Riecken, EO; Scherübl, H; Wolf, KJ; Zeitz, M	1
Alberts, SR; Cha, SS; Goldberg, RM; Jatoi, A; Kardinal, CG; Mailliard, JA; Morton, RF; Nair, S; Rowland, KM; Sargen, D; Stella, PJ; Tirona, MT	1
Artru, P; De Gramont, A; Krulik, M; Louvet, C; Nahon, P; Tournigand, C	1
Bains, M; Coit, D; Gonen, M; Ilson, DH; Karpeh, M; Kelsen, DP; Minsky, BD; O'Reilly, E; Rusch, V; Wilson, K	1
Bernhard, H; Bredenkamp, R; Hennig, M; Lordick, F; Peschel, C; von Schilling, C	1
Ajani, JA	1
Benson, AB; Blanke, CD; Hecht, JR; Lenz, HJ	1
Ajani, JA; Faust, J; Komaki, R; Putnam, JB; Rice, D; Roth, J; Smythe, R; Stevens, C; Swisher, S; Vaporciyan, A; Walsh, G; Yao, J	1
Baker, SD; Faust, J; Govindan, R; Ma, MK; McLeod, HL; Perry, MC; Read, W; Trinkaus, K	1
Ilson, DH; Minsky, B	1
Anderson, SE; Bains, M; Ilson, DH; Kelsen, DP; Minsky, BD	1
Assersohn, L; Brown, G; Cunningham, D; Hill, ME; Norman, AR; Oates, J; Ward, C; Waters, JS	1
Bagajevas, A; Cesas, A	1
Kawada, K; Kawano, T; Miyake, S; Nagai, K; Nakajima, Y; Nishikage, T; Ogiya, K; Tanaka, K; Toukairin, Y	1
Ajani, JA; Cohen, DS; Faust, J; Komaki, R; Lynch, PM; Morris, J; Nivers, R; Putnam, JB; Roth, JA; Smythe, R; Swisher, SG; Vaporciyan, A; Walsh, G; Wu, TT	1
Ajani, JA; Bresalier, R; Correa, AM; Erasmus, JJ; Komaki, R; Macapinlac, H; Maish, M; Munden, RF; Putnam, JB; Rice, D; Roth, JA; Smythe, WR; Swisher, SG; Vaporciyan, AA; Walsh, GL; Wu, TT	1
Fujiwara, Y; Fukushima, S; Hirohashi, K; Lee, S; Morimura, K; Osugi, H; Suehiro, S; Takemura, M	1
Ilson, DH	3
Chen, A; Chou, R; Lau, D	1
Bubis, JA; Dragnev, KH; Rigas, JR	1
Ajani, JA; Cox, JD; Komaki, R; Liao, Z; Liu, H; Swisher, S; Tucker, SL; Vaporciyan, AA; Wang, SL; Wei, X	1
Aggarwal, BB; Ajani, JA; Chao, KS; Ensor, J; Hittelman, WN; Izzo, JG; Lee, JH; Liao, Z; Luthra, R; Malhotra, U; Swisher, SG; Wu, TT	1
Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Kim, H; Kulke, MH; Mayer, RJ; Michelini, AL; Ryan, DP; Vincitore, MM	1
Baba, H; Endo, K; Haraguchi, M; Kohnoe, S; Maehara, Y; Nishiyama, K; Okamura, T; Toh, Y	1
Abbruzzese, JL; Atkins, JN; Blanke, CD; Dakhil, SR; Gandara, DR; McCoy, SA; Paradelo, JC; Williamson, SK; Yost, KJ	1
Anthoney, DA; Burge, ME; Halstead, F; Jackson, DP; Seymour, MT; Smith, D; Topham, C	1
Adenis, A; Boucher, E; Dahan, L; Di Fiore, F; Galais, MP; Hamidou, H; Hellot, MF; Jacob, JH; Michel, P; Mirabel, X; Paillot, B; Prod'homme, S; Raoul, JL	1
Capanu, M; D'Adamo, D; Ilson, DH; Kelsen, DP; Levnor, A; O'Reilly, E; Ramanathan, RK; Schwartz, GK; Schwartz, L; Shah, MA; Trocola, R; Tse, A	1
Ami, K; Ando, M; Ganno, H; Ito, T; Nagahama, T; Ohbu, M; Taira, M	1
Hashimoto, T; Izumi, Y; Kato, T; Kawada, K; Miura, A; Momma, K; Oota, M	1
Han, JY; Kim, HT; Kim, HY; Lee, DH; Lee, JS; Lee, SY; Yoon, SJ	1
Chan, RK; Ericsson, ML; Kung, D; Ruan, DT; Saund, MS	1
Goto, T; Kawakami, T; Kikuchi, K; Kitazawa, E; Miyakawa, H; Mizuguchi, K; Murakawa, Y; Nakano, K; Sato, S; Tajima, Y; Takai, A; Watabe, H; Watanabe, M	1
Meric, JB	1
Chrysanthopoulos, C; Gerolymos, MK; Iconomou, G; Kalofonos, HP; Kontogeorgou, E; Koutras, AK; Makatsoris, T; Tsiata, E; Vourli, G	1
Honda, M; Imutsuka, S; Korenaga, D; Nozoe, T; Yasuda, M	1
Carcereny, E; Casado, E; Fernández-Llamazares, J; Font, A; Gallego, R; Guix, M; Manzano, JL; Maurel, J; Ramirez, JL; Rosell, R; Salazar, R; Tabernero, J; Taron, M	1
DeGroff, J; Enzinger, P; Gollub, M; Gonzalez, G; Huang, Y; Ilson, DH; Kelsen, DP; Kornblith, A; O'Reilly, E; Saltz, L; Schwartz, G	1
Adjei, AA; Alberts, SA; Burch, PA; Elfring, G; Erlichman, C; Goldberg, RM; Miller, LL; Pitot, HC; Reid, JM; Rubin, J; Schaaf, LJ; Skaff, PA; Sloan, JA	1
Cvitkovic, E; Di Palma, M; Goldwasser, F; Gross-Goupil, M; Marceau-Suissa, J; Misset, JL; Tigaud, JM; Wasserman, E; Yovine, A	1
Ajani, JA; Charnsangavej, C; Fairweather, J; Pisters, PW	1
Enzinger, PC; Ilson, DH	1
Ajani, JA; Blumenshein, GR; Fairweather, JS; Feig, BW; Ho, L; Janjan, NA; Komaki, R; Lynch, PM; Pazdur, R; Pisters, PW; Raijman, I; Walsh, GL	1
Komura, Y; Matsumura, N; Okamoto, S; Sasaki, N; Taniyama, K; Uemura, N; Yamaguchi, S; Yamamoto, S	1
Ajani, JA; Baker, J; Feig, B; Ho, L; Mansfield, PF; Pisters, PW	1
Eriguchi, M; Fujii, Y; Sairenji, T	1
Law, S; Wong, J	1
Iwai, T; Kawano, T; Miyake, S; Nagai, K; Nakajima, Y	1
Ando, N; Shih, CH	1
Eguchi, K; Karato, A; Kojima, A; Kunikane, H; Ohe, Y; Ohmatsu, H; Okamoto, H; Sasaki, Y; Shinkai, T; Tamura, T	1

Reviews

19 review(s) available for irinotecan and Cancer of Esophagus

Article	Year
S-1 plus apatinib followed by salvage esophagectomy for irinotecan-refractory small cell carcinoma of the esophagus: A case report and review of the literature. Medicine, 2020, Volume: 99, Issue:3 Topics: Antimetabolites, Antineoplastic; Carcinoma, Small Cell; Drug Combinations; Drug Resistance, Neoplasm; Drug Therapy, Combination; Esophageal Neoplasms; Esophagectomy; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Protein Kinase Inhibitors; Pyridines; Salvage Therapy; Tegafur	2020
Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma. The Cochrane database of systematic reviews, 2020, 11-19, Volume: 11 Topics: Adenocarcinoma; Antineoplastic Agents; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Humans; Immunotherapy; Irinotecan; Neoplasm Recurrence, Local; Paclitaxel; Placebos; Progression-Free Survival; Quality of Life; Randomized Controlled Trials as Topic; Salvage Therapy; Stomach Neoplasms	2020
[A case of neuroendocrine cell carcinoma of the esophagus with lung metastases successfully treated with CPT-11/CDDP]. Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:12 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neoplasms; Humans; Irinotecan; Lung Neoplasms; Male; Neoadjuvant Therapy	2013
The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysis. Journal of the National Cancer Institute, 2016, Volume: 108, Issue:10 Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Capecitabine; Cisplatin; Disease-Free Survival; Drug Combinations; Esophageal Neoplasms; Esophagogastric Junction; Fluorouracil; Humans; Irinotecan; Methotrexate; Network Meta-Analysis; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Randomized Controlled Trials as Topic; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur	2016
The role of capecitabine in the management of tumors of the digestive system. Reviews on recent clinical trials, 2009, Volume: 4, Issue:1 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Cholangiocarcinoma; Colonic Neoplasms; Deoxycytidine; Digestive System Neoplasms; Docetaxel; Esophageal Neoplasms; Fluorouracil; Gallbladder Neoplasms; Humans; Irinotecan; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Rectal Neoplasms; Stomach Neoplasms; Taxoids; Treatment Outcome; Vascular Endothelial Growth Factor A	2009
Chemotherapeutic options for gastroesophageal junction tumors. Seminars in radiation oncology, 2013, Volume: 23, Issue:1 Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Esophageal Neoplasms; Esophagogastric Junction; Humans; Irinotecan; Palliative Care; Stomach Neoplasms; Taxoids	2013
Irinotecan, cisplatin, and radiation in esophageal cancer. Oncology (Williston Park, N.Y.), 2002, Volume: 16, Issue:5 Suppl 5 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Adenosquamous; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Esophageal Neoplasms; Forecasting; Humans; Irinotecan	2002
[Combined treatment of esophageal cancer: a review]. Medicina (Kaunas, Lithuania), 2004, Volume: 40 Suppl 1 Topics: Adenocarcinoma; Alcohol Drinking; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Brachytherapy; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Deoxycytidine; Diet; Dihematoporphyrin Ether; Esophageal Neoplasms; Gemcitabine; Humans; Irinotecan; Meta-Analysis as Topic; Palliative Care; Photochemotherapy; Platinum Compounds; Postoperative Care; Prospective Studies; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Risk Factors; Smoking; Taxoids; Time Factors	2004
Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. The Annals of thoracic surgery, 2004, Volume: 78, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Docetaxel; Endosonography; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Irinotecan; Life Tables; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Preoperative Care; Prognosis; Proportional Hazards Models; Radiopharmaceuticals; Radiotherapy, Adjuvant; Retrospective Studies; Sensitivity and Specificity; Survival Analysis; Taxoids; Tomography, X-Ray Computed; Treatment Outcome	2004
Docetaxel in the treatment of esophageal cancer. Seminars in oncology, 2005, Volume: 32, Issue:2 Suppl 4 Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Fluorouracil; Gemcitabine; Humans; Ifosfamide; Irinotecan; Neoadjuvant Therapy; Taxoids	2005
New developments in the treatment of esophageal cancer. Clinical advances in hematology & oncology : H&O, 2004, Volume: 2, Issue:2 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Camptothecin; Combined Modality Therapy; Disease Management; Drug Delivery Systems; Esophageal Neoplasms; Esophagectomy; Forecasting; Humans; Irinotecan; Lymph Node Excision; Neoadjuvant Therapy; Neoplasm Proteins; Prognosis; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Topoisomerase II Inhibitors	2004
[Angiogenesis targeting in gastro-intestinal cancers]. Bulletin du cancer, 2007, Volume: 94, Issue:7 Suppl Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma, Hepatocellular; Colorectal Neoplasms; Esophageal Neoplasms; Fluorouracil; Gastrointestinal Neoplasms; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Stomach Neoplasms	2007
Irinotecan and cisplatin in advanced gastric or gastroesophageal junction carcinoma. Oncology (Williston Park, N.Y.), 2000, Volume: 14, Issue:12 Suppl 1 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase II as Topic; Esophageal Neoplasms; Esophagogastric Junction; Humans; Irinotecan; Stomach Neoplasms	2000
Irinotecan in esophageal cancer. Oncology (Williston Park, N.Y.), 2000, Volume: 14, Issue:12 Suppl 1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Enzyme Inhibitors; Esophageal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Paclitaxel; Topoisomerase I Inhibitors	2000
Phase I study of irinotecan and concurrent radiation therapy for upper GI tumors. Oncology (Williston Park, N.Y.), 2000, Volume: 14, Issue:12 Suppl 1 Topics: Adolescent; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase I as Topic; Esophageal Neoplasms; Humans; Irinotecan; Maximum Tolerated Dose; Neoplasm Staging; Radiation Dosage; Radiotherapy, Adjuvant; Stomach Neoplasms	2000
Irinotecan plus cisplatin in advanced gastric or gastroesophageal junction carcinoma. Oncology (Williston Park, N.Y.), 2001, Volume: 15, Issue:3 Suppl 5 Topics: Antineoplastic Agents; Camptothecin; Cisplatin; Esophageal Neoplasms; Esophagogastric Junction; Humans; Irinotecan; Stomach Neoplasms	2001
New adjuvant therapies for esophageal cancer. Advances in surgery, 2001, Volume: 35 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Digestive System Surgical Procedures; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Irinotecan; Neoadjuvant Therapy; Paclitaxel; Radiotherapy, Adjuvant; Taxoids	2001
New developments in the treatment of esophageal cancer. Current oncology reports, 2002, Volume: 4, Issue:3 Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Esophageal Neoplasms; Humans; Irinotecan; Paclitaxel; Survival Rate	2002
[Chemotherapy for the patients with esophageal cancer]. Nihon Geka Gakkai zasshi, 2002, Volume: 103, Issue:4 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Esophageal Neoplasms; Fluorouracil; Humans; Irinotecan; Neoadjuvant Therapy; Paclitaxel	2002

Trials

64 trial(s) available for irinotecan and Cancer of Esophagus

Article	Year
Impact of Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer on Health-Related Quality of Life in KEYNOTE-181. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 02-01, Volume: 40, Issue:4 Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Disease Progression; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Functional Status; Humans; Immune Checkpoint Inhibitors; Irinotecan; Paclitaxel; Quality of Life; Surveys and Questionnaires; Time Factors; Treatment Outcome	2022
Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2). Nature communications, 2022, 02-14, Volume: 13, Issue:1 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Immune Checkpoint Inhibitors; Irinotecan; Male; Middle Aged; Paclitaxel; Programmed Cell Death 1 Receptor; Progression-Free Survival; Receptors, Antigen, T-Cell	2022
Rh-Endostatin Plus Irinotecan/Cisplatin as Second-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma: An Open-Label, Phase II Study. The oncologist, 2022, 04-05, Volume: 27, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Endostatins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Irinotecan	2022
Radiotherapy plus camrelizumab and irinotecan for oligometastatic esophageal squamous cell carcinoma patients after first-line immunotherapy plus chemotherapy failure: An open-label, single-arm, phase II trial. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2023, Volume: 184 Topics: Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Immunotherapy; Irinotecan	2023
Efficacy and safety of irinotecan combined with raltitrexed or irinotecan monotherapy for salvage chemotherapy of esophageal squamous cell cancer: A prospective, open label, randomized phase II study. Cancer medicine, 2023, Volume: 12, Issue:15 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Irinotecan; Prospective Studies	2023
Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II study. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2020, Volume: 52, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Disease Progression; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; France; Humans; Irinotecan; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Survival Rate	2020
Evaluation of the Association of Perioperative UGT1A1 Genotype-Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma: A Phase 2 Clinical Trial. JAMA network open, 2020, 02-05, Volume: 3, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Female; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Positron-Emission Tomography; Stomach Neoplasms	2020
Nivolumab in Combination with Irinotecan and 5-Fluorouracil (FOLFIRI) for Refractory Advanced Gastroesophageal Cancer. Oncology, 2020, Volume: 98, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Nivolumab; Prognosis; Progression-Free Survival; Retrospective Studies; Stomach Neoplasms	2020
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. The New England journal of medicine, 2020, 06-18, Volume: 382, Issue:25 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Marrow; Camptothecin; Esophageal Neoplasms; Female; Humans; Immunoconjugates; Irinotecan; Lung Diseases, Interstitial; Male; Middle Aged; Paclitaxel; Receptor, ErbB-2; Stomach Neoplasms; Survival Analysis; Trastuzumab	2020
FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers: A Phase 2 Nonrandomized Clinical Trial. JAMA oncology, 2020, 08-01, Volume: 6, Issue:8 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Esophageal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Nausea; Neutropenia; Oxaliplatin; Peripheral Nervous System Diseases; Stomach Neoplasms; Trastuzumab; Treatment Outcome	2020
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020, 12-10, Volume: 38, Issue:35 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Irinotecan; Male; Middle Aged; Paclitaxel; Progression-Free Survival; Survival Rate; Young Adult	2020
HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial. Journal for immunotherapy of cancer, 2020, Volume: 8, Issue:2 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Irinotecan; Male; Middle Aged; Stomach Neoplasms	2020
Preoperative Capecitabine, Oxaliplatin, and Irinotecan in Resectable Gastric or Gastroesophageal Junction Cancer: Pathological Response as Primary Endpoint and FDG-PET Predictions. Oncology, 2017, Volume: 93, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Capecitabine; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorodeoxyglucose F18; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Positron Emission Tomography Computed Tomography; Postoperative Care; Preoperative Care; Stomach Neoplasms	2017
Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300. Annals of oncology : official journal of the European Society for Medical Oncology, 2018, 10-01, Volume: 29, Issue:10 Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Papillary; Carcinoma, Signet Ring Cell; Choice Behavior; Decision Support Techniques; Esophageal Neoplasms; Esophagogastric Junction; Female; Follow-Up Studies; Humans; International Agencies; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Practice Patterns, Physicians'; Prognosis; Stomach Neoplasms; Survival Rate; Young Adult	2018
Neoadjuvant chemotherapy with irinotecan and nedaplatin in a single cycle followed by esophagectomy on cT4 resectable esophageal squamous cell carcinoma: a prospective nonrandomized trial for short-term outcomes. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2019, Mar-01, Volume: 32, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Female; Humans; Irinotecan; Male; Neoadjuvant Therapy; Organoplatinum Compounds; Prospective Studies; Survival Rate; Treatment Outcome	2019
The influence of prior ramucirumab treatment on the clinical activity of FOLFIRI as third-line therapy in patients with metastatic gastric Cancer. Investigational new drugs, 2019, Volume: 37, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Prognosis; Ramucirumab; Stomach Neoplasms; Survival Rate	2019
Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial. Cancer communications (London, England), 2019, 04-02, Volume: 39, Issue:1 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Combinations; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Tegafur; Topoisomerase I Inhibitors	2019
Combination of apatinib mesylate and second-line chemotherapy for treating gastroesophageal junction adenocarcinoma. The Journal of international medical research, 2019, Volume: 47, Issue:5 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Squamous Cell; Case-Control Studies; Cisplatin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Prognosis; Pyridines; Stomach Neoplasms; Survival Rate; Taxoids	2019
A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:6 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Camptothecin; Docetaxel; Drug Carriers; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Irinotecan; Male; Middle Aged; Nanocapsules; Stomach Neoplasms; Survival Rate; Taxoids	2013
Preoperative cetuximab, irinotecan, cisplatin, and radiation therapy for patients with locally advanced esophageal cancer. The oncologist, 2013, Volume: 18, Issue:3 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Chemoradiotherapy, Adjuvant; Cisplatin; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Preoperative Care; Prospective Studies; Stomach Neoplasms; Young Adult	2013
Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach. Investigational new drugs, 2014, Volume: 32, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Camptothecin; Esophageal Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Proteasome Inhibitors; Pyrazines; Stomach Neoplasms	2014
Eastern Cooperative Oncology Group and American College of Radiology Imaging Network Randomized Phase 2 Trial of Neoadjuvant Preoperative Paclitaxel/Cisplatin/Radiation Therapy (RT) or Irinotecan/Cisplatin/RT in Esophageal Adenocarcinoma: Long-Term Outcom International journal of radiation oncology, biology, physics, 2016, Mar-15, Volume: 94, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Esophageal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Radiotherapy Dosage; Survival Rate	2016
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, 08-10, Volume: 34, Issue:23 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Disease Progression; Disease-Free Survival; Epirubicin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Survival Rate; Time Factors; Treatment Failure	2016
Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer. BMC cancer, 2016, 07-13, Volume: 16 Topics: Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celecoxib; Chemoradiotherapy; Chemotherapy-Induced Febrile Neutropenia; Cisplatin; Cyclooxygenase 2 Inhibitors; Deglutition Disorders; Disease-Free Survival; Drug Administration Schedule; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Irinotecan; Male; Middle Aged; Nausea; Neoadjuvant Therapy; Neoplasm Staging	2016
Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:8 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Quality of Life; Stomach Neoplasms	2008
A phase II trial evaluating capecitabine and irinotecan as second line treatment in patients with oesophago-gastric cancer who have progressed on, or within 3 months of platinum-based chemotherapy. Cancer chemotherapy and pharmacology, 2009, Volume: 64, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Disease Progression; Disease-Free Survival; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Stomach Neoplasms; Survival Rate; Time Factors; Treatment Outcome	2009
Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Stomach Neoplasms; Taxoids	2009
Phase I study of weekly cisplatin, bolus fluorouracil and escalating doses of irinotecan in advanced solid tumors. Cancer investigation, 2009, Volume: 27, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Diarrhea; Digestive System Neoplasms; Disease Progression; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Pancreatic Neoplasms; Stomach Neoplasms; Time Factors; Treatment Outcome	2009
Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:7 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Disease Progression; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Survival Analysis; Taxoids; Treatment Outcome	2009
Phase II trial of preoperative irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for resectable locally advanced gastric and esophagogastric junction adenocarcinoma. International journal of radiation oncology, biology, physics, 2009, Dec-01, Volume: 75, Issue:5 Topics: Adenocarcinoma; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Esophageal Neoplasms; Esophagogastric Junction; Humans; Irinotecan; Preoperative Period; Prospective Studies; Remission Induction; Spain; Stomach Neoplasms; Survival Rate	2009
Phase II trial of induction irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for unresectable, locally advanced gastric and oesophageal-gastric junction adenocarcinoma. Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:1 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Esophagogastric Junction; Follow-Up Studies; Humans; Irinotecan; Stomach Neoplasms; Survival Rate	2011
Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma. Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Stomach Neoplasms; Taxoids; Treatment Outcome	2010
Phase II randomized study of two regimens of sequentially administered mitomycin C and irinotecan in patients with unresectable esophageal and gastroesophageal adenocarcinoma. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010, Volume: 5, Issue:5 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Carcinoma, Squamous Cell; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mitomycin; Neoplasm Staging; Stomach Neoplasms; Survival Rate; Treatment Outcome	2010
Phase 2 trial of preoperative irinotecan plus cisplatin and conformal radiotherapy, followed by surgery for esophageal cancer. Cancer, 2010, Sep-01, Volume: 116, Issue:17 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Radiotherapy, Conformal	2010
Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study. Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:6 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Esophageal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Stomach Neoplasms; Treatment Outcome	2011
Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer. Cancer, 2012, Jun-01, Volume: 118, Issue:11 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Female; Humans; Induction Chemotherapy; Irinotecan; Male; Middle Aged; Neoplasms, Squamous Cell; Positron-Emission Tomography	2012
Phase II study of biweekly cetuximab in combination with irinotecan as second-line treatment in patients with platinum-resistant gastro-oesophageal cancer. European journal of cancer (Oxford, England : 1990), 2012, Volume: 48, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Drug Administration Schedule; Drug Resistance, Neoplasm; Esophageal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Stomach Neoplasms; Survival Analysis	2012
Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414). Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2012, Volume: 7, Issue:5 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Prognosis; Remission Induction; Survival Rate; Thoracic Neoplasms	2012
Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study. British journal of cancer, 2012, Jul-24, Volume: 107, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Stomach Neoplasms; Taxoids	2012
Phase II trial of cetuximab plus cisplatin and irinotecan in patients with cisplatin and irinotecan-refractory metastatic esophagogastric cancer. American journal of clinical oncology, 2014, Volume: 37, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Esophageal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Stomach Neoplasms; Treatment Outcome	2014
Irinotecan/cisplatin in advanced, treated gastric or gastroesophageal junction carcinoma. Oncology (Williston Park, N.Y.), 2002, Volume: 16, Issue:5 Suppl 5 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease Progression; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Irinotecan; Male; Middle Aged; Stomach Neoplasms; Survival Rate	2002
A pilot study of irinotecan (CPT-11) as single-agent therapy in patients with locally advanced or metastatic esophageal carcinoma. International journal of colorectal disease, 2003, Volume: 18, Issue:4 Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Disease Progression; Esophageal Neoplasms; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neutropenia; Survival Analysis	2003
A phase II trial of docetaxel and CPT-11 in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and gastric cardia. International journal of gastrointestinal cancer, 2002, Volume: 32, Issue:2-3 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cardia; Docetaxel; Dose-Response Relationship, Drug; Esophageal Neoplasms; Female; Humans; Hypotension; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Nausea; Paclitaxel; Stomach Neoplasms; Taxoids; Treatment Outcome; Vomiting	2002
Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Aug-01, Volume: 21, Issue:15 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Adenosquamous; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Treatment Outcome	2003
Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer. British journal of cancer, 2003, Aug-18, Volume: 89, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Esophageal Neoplasms; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Salvage Therapy; Survival Rate; Taxoids; Treatment Outcome	2003
Irinotecan/cisplatin followed by 5-FU/paclitaxel/radiotherapy and surgery in esophageal cancer. Oncology (Williston Park, N.Y.), 2003, Volume: 17, Issue:9 Suppl 8 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Paclitaxel; Radiotherapy, Adjuvant	2003
Phase II study of docetaxel and irinotecan in metastatic or recurrent esophageal cancer: a preliminary report. Oncology (Williston Park, N.Y.), 2003, Volume: 17, Issue:9 Suppl 8 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Esophageal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Recurrence; Survival Analysis; Taxoids; Treatment Outcome	2003
Irinotecan in esophageal cancer. Oncology (Williston Park, N.Y.), 2003, Volume: 17, Issue:9 Suppl 8 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Esophageal Neoplasms; Humans; Irinotecan; Radiotherapy, Adjuvant; Treatment Outcome	2003
Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Stomach Neoplasms; Treatment Outcome	2004
Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer. Oncology (Williston Park, N.Y.), 2004, Volume: 18, Issue:14 Suppl 1 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Esophageal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Time Factors	2004
Association of activated transcription factor nuclear factor kappab with chemoradiation resistance and poor outcome in esophageal carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Feb-10, Volume: 24, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Gene Expression Profiling; Humans; Immunohistochemistry; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; NF-kappa B; Prognosis; Taxoids; Treatment Outcome	2006
A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma. Digestive diseases and sciences, 2005, Volume: 50, Issue:12 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Esophageal Neoplasms; Esophagogastric Junction; Female; Follow-Up Studies; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Palliative Care; Prospective Studies; Stomach Neoplasms; Survival Analysis; Terminally Ill; Treatment Outcome	2005
Phase II trial of gemcitabine plus irinotecan in patients with esophageal cancer: a Southwest Oncology Group (SWOG) trial. American journal of clinical oncology, 2006, Volume: 29, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Esophageal Neoplasms; Female; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Survival Analysis; Treatment Outcome	2006
A phase I and II study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma. British journal of cancer, 2006, May-08, Volume: 94, Issue:9 Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Stomach Neoplasms; Survival Analysis; Treatment Outcome	2006
Induction cisplatin-irinotecan followed by concurrent cisplatin-irinotecan and radiotherapy without surgery in oesophageal cancer: multicenter phase II FFCD trial. British journal of cancer, 2006, Sep-18, Volume: 95, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deglutition Disorders; Dose Fractionation, Radiation; Esophageal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Remission Induction; Survival Rate; Treatment Outcome	2006
Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Nov-20, Volume: 24, Issue:33 Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cisplatin; Disease Progression; Disease-Free Survival; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Stomach Neoplasms; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A	2006
A phase II trial of modified weekly irinotecan and cisplatin for chemotherapy-naïve patients with metastatic or recurrent squamous cell carcinoma of the esophagus. Cancer chemotherapy and pharmacology, 2008, Volume: 61, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Esophageal Neoplasms; Female; Hematologic Diseases; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Salvage Therapy; Survival Rate	2008
Phase II study of irinotecan plus leucovorin and bolus 5-fluorouracil as first- or second-line chemotherapy in patients with advanced gastric or esophageal-gastric junction adenocarcinoma. Journal of chemotherapy (Florence, Italy), 2007, Volume: 19, Issue:6 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Stomach Neoplasms	2007
Cisplatin plus weekly CPT-11/docetaxel in advanced esophagogastric cancer: a phase I study with pharmacogenetic assessment of XPD, XRCC3 and UGT1A1 polymorphisms. Cancer chemotherapy and pharmacology, 2008, Volume: 62, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Diarrhea; Disease Progression; Disease-Free Survival; DNA Repair; DNA-Binding Proteins; Docetaxel; Drug Resistance, Neoplasm; Esophageal Neoplasms; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasm Proteins; Neutropenia; Polymorphism, Single Nucleotide; Stomach Neoplasms; Survival Analysis; Taxoids; Xeroderma Pigmentosum Group D Protein	2008
Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:10 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Deglutition Disorders; Drug Administration Schedule; Esophageal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Quality of Life; Survival Analysis; Treatment Outcome	1999
Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy. Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:6 Topics: Adjuvants, Anesthesia; Adult; Aged; Aged, 80 and over; Antidiarrheals; Antiemetics; Antineoplastic Agents, Phytogenic; Area Under Curve; Atropine; Camptothecin; Colorectal Neoplasms; Dexamethasone; Digestive System; Dose-Response Relationship, Drug; Esophageal Neoplasms; Female; Follow-Up Studies; Gallbladder Neoplasms; Glucuronates; Humans; Irinotecan; Loperamide; Male; Maximum Tolerated Dose; Middle Aged; Time Factors	2000
Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: a phase I study in advanced gastrointestinal cancer patients. Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:11 Topics: Adult; Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Esophageal Neoplasms; Female; Fluorouracil; Gastrointestinal Neoplasms; Hematologic Diseases; Humans; Infections; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy; Sensation Disorders; Treatment Outcome	2000
CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study. Cancer, 2002, Feb-01, Volume: 94, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Esophageal Neoplasms; Fatigue; Female; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Stomach Neoplasms; Treatment Outcome	2002
Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion. Journal of the National Cancer Institute, 1992, Jun-17, Volume: 84, Issue:12 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Diarrhea; Drug Evaluation; Esophageal Neoplasms; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Middle Aged; Pharyngeal Neoplasms	1992

Other Studies

48 other study(ies) available for irinotecan and Cancer of Esophagus

Article	Year
Clinical efficacy of irinotecan plus raltitrexed chemotherapy in refractory esophageal squamous cell cancer. Anti-cancer drugs, 2020, Volume: 31, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Retrospective Studies; Salvage Therapy; Survival Rate; Thiophenes	2020
A multifunctional SN38-conjugated nanosystem for defeating myelosuppression and diarrhea induced by irinotecan in esophageal cancer. Nanoscale, 2020, Oct-29, Volume: 12, Issue:41 Topics: Animals; Cell Line, Tumor; Diarrhea; Esophageal Neoplasms; Irinotecan; Manganese Compounds; Mice; Nanoparticles; Oxides; Phototherapy; Tumor Microenvironment	2020
A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2017, Jul-01, Volume: 30, Issue:7 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Patient Readmission; Radiotherapy Dosage; Retrospective Studies; Survival Rate; Young Adult	2017
[A Case of Resected Esophageal Endocrine Cell Carcinoma That Responded to Combination Therapy Comprising Irinotecan and Cisplatin]. Gan to kagaku ryoho. Cancer & chemotherapy, 2018, Volume: 45, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Endocrine Cells; Esophageal Neoplasms; Esophagectomy; Fatal Outcome; Female; Humans; Irinotecan; Neoadjuvant Therapy	2018
Safety and Effectiveness of Chemotherapy for Metastatic Esophageal Cancer in a Community Hospital in Brazil. Journal of global oncology, 2019, Volume: 5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brazil; Carcinoma, Squamous Cell; Esophageal Neoplasms; Hospitals, Community; Humans; Irinotecan; Middle Aged; Neoplasms, Multiple Primary; Paclitaxel; Platinum; Retrospective Studies; Survival Analysis; Treatment Outcome	2019
Two-stage operation for synchronous triple primary cancer of the esophagus, stomach, and ampulla of Vater: report of a case. Surgery today, 2014, Volume: 44, Issue:5 Topics: Adenocarcinoma; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Common Bile Duct Neoplasms; Diagnostic Imaging; Digestive System Surgical Procedures; Esophageal Neoplasms; Fatal Outcome; Humans; Irinotecan; Lymph Node Excision; Male; Neoplasms, Multiple Primary; Plastic Surgery Procedures; Prostatic Neoplasms; Stomach Neoplasms	2014
Associations between UGT1A16/28 polymorphisms and irinotecan-induced severe toxicity in Chinese gastric or esophageal cancer patients. Medical oncology (Northwood, London, England), 2013, Volume: 30, Issue:3 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Asian People; Camptothecin; Esophageal Neoplasms; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Polymorphism, Genetic; Retrospective Studies; Stomach Neoplasms; Young Adult	2013
Outcomes of induction chemotherapy followed by chemoradiation using intensity-modulated radiation therapy for esophageal adenocarcinoma. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2014, Volume: 27, Issue:3 Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy, Adjuvant; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Induction Chemotherapy; Irinotecan; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Platinum Compounds; Radiotherapy, Intensity-Modulated; Survival Rate; Tumor Burden	2014
Second primary pancreatic adenocarcinoma three years after successfully treated index esophageal cancer. JOP : Journal of the pancreas, 2014, Jan-10, Volume: 15, Issue:1 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cholangitis; Combined Modality Therapy; Esophageal Neoplasms; Esophagectomy; Fatal Outcome; Fluorouracil; Gastrectomy; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Neoplasms, Second Primary; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Pancreaticoduodenectomy; Sepsis	2014
Irinotecan plus cisplatin in patients with extensive-disease poorly differentiated neuroendocrine carcinoma of the esophagus. Anticancer research, 2014, Volume: 34, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Cisplatin; Esophageal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Treatment Outcome	2014
A case series of patients with HER2-overexpressed primary metastatic gastroesophageal adenocarcinoma. Anticancer research, 2014, Volume: 34, Issue:12 Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Camptothecin; Capecitabine; Carboplatin; Deoxycytidine; Esophageal Neoplasms; Esophagogastric Junction; Fluorouracil; Humans; Irinotecan; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Receptor, ErbB-2; Retrospective Studies; Stomach Neoplasms; Trastuzumab	2014
[A Case of Esophageal Neuroendocrine Carcinoma for Which Irinotecan and Cisplatin Combination Therapy Was Effective]. Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:8 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Cisplatin; Deglutition Disorders; Esophageal Neoplasms; Humans; Irinotecan; Lymphatic Metastasis; Male; Tomography, X-Ray Computed	2015
[Second-line treatment for metastatic or locally advanced gastric cancer]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2016, Oct-23, Volume: 38, Issue:10 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Humans; Irinotecan; Molecular Targeted Therapy; Paclitaxel; Ramucirumab; Salvage Therapy; Stomach Neoplasms; Taxoids	2016
Irinotecan plus cisplatin for therapy of small-cell carcinoma of the esophagus: report of 12 cases from single institution experience. Japanese journal of clinical oncology, 2008, Volume: 38, Issue:6 Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Esophageal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Retrospective Studies; Survival Analysis; Treatment Outcome	2008
[A fatal case of small cell type undifferentiated carcinoma of the esophagus with sudden diarrhea and bloody discharge by CPT-11]. Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cell Differentiation; Cisplatin; Diarrhea; Esophageal Neoplasms; Fatal Outcome; Hemorrhage; Humans; Irinotecan; Male; Middle Aged; Treatment Failure	2008
[A case of recurrent gastroesophageal junction adenocarcinoma successfully treated with radiation plus chemotherapy (5-FU+CDDP, S-1, Paclitaxel, CPT-11) for long-term survival with good QOL]. Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:11 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Drug Combinations; Esophageal Neoplasms; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; Oxonic Acid; Paclitaxel; Quality of Life; Stomach Neoplasms; Tegafur; Time Factors; Tomography, X-Ray Computed	2008
[CDDP+CPT-11 therapy is useful for stage IVb esophageal small cell carcinoma]. Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Esophageal Neoplasms; Esophagoscopy; Fatal Outcome; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Tomography, X-Ray Computed	2009
Triterpenes augment the inhibitory effects of anticancer drugs on growth of human esophageal carcinoma cells in vitro and suppress experimental metastasis in vivo. International journal of cancer, 2009, Aug-15, Volume: 125, Issue:4 Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Interactions; Drug Synergism; Esophageal Neoplasms; Fluorouracil; Humans; In Vitro Techniques; Irinotecan; Male; Mice; Mice, Nude; Mice, SCID; Peritoneal Neoplasms; Plant Preparations; Prunus; Triterpenes; Xenograft Model Antitumor Assays	2009
[A case of superficial small cell carcinoma of the esophagus]. Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:9 Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Esophageal Neoplasms; Esophagectomy; Humans; Irinotecan; Male	2009
Cisplatin/Irinotecan versus carboplatin/paclitaxel as definitive chemoradiotherapy for locoregionally advanced esophageal cancer. American journal of clinical oncology, 2010, Volume: 33, Issue:4 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Survival Rate	2010
Choroidal metastases from esophageal adenocarcinoma responding to chemotherapy with cisplatin and irinotecan. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Aug-01, Volume: 28, Issue:22 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Choroid Neoplasms; Cisplatin; Esophageal Neoplasms; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged	2010
Toxicity, response rates and survival outcomes of induction cisplatin and irinotecan followed by concurrent cisplatin, irinotecan and radiotherapy for locally advanced esophageal cancer. Japanese journal of clinical oncology, 2011, Volume: 41, Issue:3 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Esophagitis; Female; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Neutropenia; Radiotherapy; Survival Rate; Treatment Outcome	2011
[A case of small cell carcinoma of esophagus treated by chemotherapy with CDDP plus CPT-11 and radiotherapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:12 Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Female; Humans; Irinotecan; Lymphatic Metastasis	2010
Docetaxel and irinotecan as second-line therapy for advanced oesophagogastric cancer. European journal of cancer (Oxford, England : 1990), 2011, Volume: 47, Issue:8 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Disease Progression; Docetaxel; Esophageal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Prognosis; Retrospective Studies; Stomach Neoplasms; Taxoids; Treatment Outcome	2011
Biweekly cetuximab and irinotecan as second-line therapy in patients with gastro-esophageal cancer previously treated with platinum. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2011, Volume: 14, Issue:3 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Salvage Therapy; Stomach Neoplasms; Survival Rate; Treatment Outcome	2011
Palliative first-line therapy with weekly high-dose 5-fluorouracil and sodium folinic acid as a 24-hour infusion (AIO regimen) combined with weekly irinotecan in patients with metastatic adenocarcinoma of the stomach or esophagogastric junction followed b Medical science monitor : international medical journal of experimental and clinical research, 2011, Volume: 17, Issue:5 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Palliative Care; Prognosis; Radionuclide Imaging; Stomach Neoplasms; Treatment Outcome	2011
Esophageal small-cell carcinoma with syndrome of inappropriate secretion of antidiuretic hormone. Internal medicine (Tokyo, Japan), 2011, Volume: 50, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Esophageal Neoplasms; Fatal Outcome; Humans; Hyponatremia; Inappropriate ADH Syndrome; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Neuroendocrine Tumors; Paraneoplastic Endocrine Syndromes	2011
Efficacy of irinotecan in combination with 5-fluorouracil (FOLFIRI) for metastatic gastric or gastroesophageal junction adenocarcinomas (MGA) treatment. Clinics and research in hepatology and gastroenterology, 2011, Volume: 35, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Retrospective Studies; Stomach Neoplasms	2011
A pilot trial of S-1 plus irinotecan chemotherapy for esophageal adenocarcinoma. Hepato-gastroenterology, 2012, Volume: 59, Issue:119 Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Oxonic Acid; Pilot Projects; Survival Analysis; Tegafur; Time Factors; Treatment Outcome	2012
Irinotecan, cisplatin and mitomycin in inoperable gastro-oesophageal and pancreatic cancers - a new active regimen. British journal of cancer, 2002, Oct-07, Volume: 87, Issue:8 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Esophageal Neoplasms; Female; Gastrointestinal Diseases; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Mitomycin; Neutropenia; Pancreatic Neoplasms; Stomach Neoplasms; Treatment Outcome	2002
[Renal metastasis after curative resection of an epidermoid carcinoma of the esophagus]. Gastroenterologie clinique et biologique, 2003, Volume: 27, Issue:5 Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Deglutition Disorders; Esophageal Neoplasms; Esophagectomy; Esophagoscopy; Fluorouracil; Humans; Irinotecan; Kidney Neoplasms; Lymphatic Metastasis; Male; Neoplasm Staging; Prognosis; Tomography, X-Ray Computed	2003
Irinotecan and other agents in upper gastrointestinal and colorectal carcinomas. The University of Texas M. D. Anderson Cancer Center Investigators' Workshop, Volume 3. Introduction. Oncology (Williston Park, N.Y.), 2003, Volume: 17, Issue:9 Suppl 8 Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Esophageal Neoplasms; Esophagogastric Junction; Humans; Irinotecan	2003
Irinotecan and paclitaxel in metastatic adenocarcinoma of the esophagus and gastric cardia. Oncology (Williston Park, N.Y.), 2003, Volume: 17, Issue:9 Suppl 8 Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cardia; Esophageal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Paclitaxel; Stomach Neoplasms	2003
Combined modality therapy in esophageal cancer: the Memorial experience. Seminars in surgical oncology, 2003, Volume: 21, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Fluorouracil; Humans; Irinotecan; Neoadjuvant Therapy; Paclitaxel	2003
The expressions of p21 and pRB may be good indicators for the sensitivity of esophageal squamous cell cancers to CPT-11: Cell proliferation activity correlates with the effect of CPT-11. Cancer science, 2004, Volume: 95, Issue:5 Topics: Adenovirus E1A Proteins; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Bromodeoxyuridine; Camptothecin; Carcinoma, Squamous Cell; Carrier Proteins; Cell Cycle; Cell Cycle Proteins; Cell Division; DNA Topoisomerases, Type I; Enzyme-Linked Immunosorbent Assay; Esophageal Neoplasms; Gene Expression Profiling; Humans; Immunohistochemistry; Irinotecan; Nuclear Proteins; Proto-Oncogene Proteins p21(ras); Repressor Proteins; Tumor Cells, Cultured	2004
Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction. Cancer, 2004, Jun-01, Volume: 100, Issue:11 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Endosonography; Esophageal Neoplasms; Esophagogastric Junction; Feasibility Studies; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Preoperative Care; Prognosis; Remission Induction; Survival Rate	2004
Suppressive effect of CPT-11 on rat esophageal tumorigenesis induced by N-nitrosomethylbenzylamine. Oncology reports, 2004, Volume: 12, Issue:6 Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Dimethylnitrosamine; Disease Models, Animal; DNA, Single-Stranded; Esophageal Neoplasms; Immunohistochemistry; Irinotecan; Male; Precancerous Conditions; Proliferating Cell Nuclear Antigen; Rats; Tumor Suppressor Protein p53	2004
Complete response of brain metastases to irinotecan-based chemotherapy. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2005, Volume: 12, Issue:3 Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Carcinoma, Small Cell; Esophageal Neoplasms; Female; Humans; Irinotecan; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Parotid Neoplasms	2005
Investigation of clinical and dosimetric factors associated with postoperative pulmonary complications in esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery. International journal of radiation oncology, biology, physics, 2006, Mar-01, Volume: 64, Issue:3 Topics: Analysis of Variance; Camptothecin; Combined Modality Therapy; Esophageal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Length of Stay; Logistic Models; Lung; Male; Pneumonia; Postoperative Complications; Radiotherapy Dosage; Radiotherapy, Conformal; Respiratory Distress Syndrome; Retrospective Studies; Sex Factors; Statistics, Nonparametric	2006
A case of esophageal small cell carcinoma with multiple liver metastases responding to chemotherapy with irinotecan plus cisplatin. Journal of experimental & clinical cancer research : CR, 2005, Volume: 24, Issue:4 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Esophageal Neoplasms; Humans; Irinotecan; Liver Neoplasms; Male; Tomography, X-Ray Computed	2005
[A case report of small cell carcinoma of the esophagus successfully treated by irinotecan and cisplatin]. Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:12 Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Docetaxel; Esophageal Neoplasms; Humans; Irinotecan; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Taxoids	2006
[Superficial small cell carcinoma of esophagus treated by endoscopic mucosal resection combined with chemoradiotherapy--a case report]. Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Esophageal Neoplasms; Esophagectomy; Esophagoscopes; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Mucous Membrane	2007
Pneumatosis intestinalis and portal venous gas without bowel ischemia in a patient treated with irinotecan and cisplatin. Digestive diseases and sciences, 2008, Volume: 53, Issue:1 Topics: Aged; Antineoplastic Agents; Camptothecin; Cisplatin; Colon; Diagnosis, Differential; Embolism, Air; Esophageal Neoplasms; Follow-Up Studies; Humans; Intestine, Small; Irinotecan; Ischemia; Laparotomy; Male; Pneumatosis Cystoides Intestinalis; Portal Vein; Prodrugs; Tomography, X-Ray Computed	2008
[A case of small cell carcinoma of the esophagus with remarkable response to chemotherapy with CPT-11 and CDDP]. Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2007, Volume: 104, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Esophageal Neoplasms; Humans; Irinotecan; Liver Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Remission Induction	2007
Experimental evidence for the efficacy of combined therapy of CPT-11 and hyperthermia for squamous cell carcinoma of the esophagus. Hepato-gastroenterology, 2007, Volume: 54, Issue:80 Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Combined Modality Therapy; Esophageal Neoplasms; Humans; Hyperthermia, Induced; Irinotecan	2007
[A case of small cell carcinoma of esophagus successfully treated by chemotherapy with CPT-11 and CDDP]. Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2001, Volume: 98, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Esophageal Neoplasms; Humans; Irinotecan; Male; Middle Aged	2001
[A case of esophageal small-cell carcinoma responding to chemotherapy with CTP-11]. Gan to kagaku ryoho. Cancer & chemotherapy, 2001, Volume: 28, Issue:9 Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Small Cell; Drug Administration Schedule; Esophageal Neoplasms; Humans; Irinotecan; Male; Middle Aged	2001
CPT-11 may provide therapeutic efficacy for esophageal squamous cell cancer and the effects correlate with the level of DNA topoisomerase I protein. Japanese journal of cancer research : Gann, 2001, Volume: 92, Issue:12 Topics: Blotting, Western; Camptothecin; Cell Division; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Esophageal Neoplasms; Humans; Irinotecan; Neoplasms, Squamous Cell; RNA, Messenger; Tumor Cells, Cultured	2001